7 results
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
Summary of dosing ... hypoglycaemic agents #Diabetes ... #Diabetic #Medications ... Renal #Impairment #CKD ... #Table #GFR #Hypoglycemics
Adjusted Pain Medication Dosing based on GFR

#Renal #Dosing #Pain #Pharmacology #Opiates #CKD #Gabapentin #Table
based on GFR ... #Renal #Dosing # ... Pain #Pharmacology ... #Opiates #CKD # ... Gabapentin #Table
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... Improved outcomes in CKD ... EricsMedicalLectures/featured #diabetes ... endocrinology #dm2
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
(stage IV or V CKD ... including most type 1 diabetics ... including most 2 diabetics ... endocrinology #diabetes ... #DM2
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - Pharmacology ... Summary Mechanisms ... contraindicated in CKD ... #Summary #DM2 # ... diabetes #endocrinology
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
Management of Diabetes ... Patients With CKD ... or Type 2 diabetes ... and CKD should ... #Diabetes #CKD #
Veltassa (Patiromer) 
MECHANISM: Potassium Binder 
INDICATION: Treatment of Hyperkalemia 
FORMULATION: Powder for oral suspension 
DOSING: 8.4
oral suspension DOSING ... 25.2 g if needed, based ... patients with CKD ... , HF, or diabetes ... #Hyperkalemia #Pharmacology